Loading...
Use of medications with pharmacogenomic guidelines and adverse outcomes in hospitalised older patients: a retrospective cross-sectional study
David, Victoria McInernay, C.D. Sagoo, G.S. Cheong, V-Lin Smith, H. Rattray, Marcus
David, Victoria
McInernay, C.D.
Sagoo, G.S.
Cheong, V-Lin
Smith, H.
Rattray, Marcus
Publication Date
2026-01-28
End of Embargo
Supervisor
Keywords
Rights
©2026 The Author(s). This is an Open Access article distributed under the Creative Commons CC-BY license (https://creativecommons.org/licenses/by/4.0/)
Peer-Reviewed
Yes
Open Access status
openAccess
Accepted for publication
2026-01-05
Institution
Department
Awarded
Embargo end date
Collections
Files
Loading...
david_et_al_2026.pdf
Adobe PDF, 630.24 KB
Additional title
Abstract
This study aimed to assess the prevalence of the use of medications with pharmacogenomic guidelines upon hospital admission in patients aged 65 and over and evaluate its association with adverse outcomes, including length of stay, unplanned admissions, and repeat hospital admissions. A retrospective cross-sectional study was conducted using hospital admissions data from 2018–2019 in one NHS hospital trust in England, focusing on patients aged 65 and over. The usage of medications with pharmacogenomic guidelines was examined, and comparisons were made between their prevalence in unplanned and planned admissions. Multivariable models assessed whether the use of medications with pharmacogenomic guidelines were associated with adverse outcomes, considering frailty status. Analysis of 59,973 admissions revealed 67 pharmacogenomics medicines as per the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, with 11 classified as high-risk among 1438 unique medicines identified from 560,179 recorded medications. Notably, unplanned admissions exhibited a higher prevalence of medications with pharmacogenomic guidelines (84% versus 64%, p < 0.001) compared to planned admissions. The models demonstrated the usage of these medications was associated with adverse outcomes (length of stay in hospital, unplanned admission and repeat hospital admission) with substantial evidence (Delta_AICc < 2) particularly in patients with high frailty status. This study highlights the association between medications with pharmacogenomic guidelines and adverse outcomes, particularly among patients with high frailty. The findings emphasise the importance of integrating pharmacogenomic-guided care into the management of older individuals with frailty to mitigate adverse outcomes and enhance medication safety.
Version
Published version
Citation
David V, McInernay CD, Tomlinson J et al (2026) Use of medications with pharmacogenomic guidelines and adverse outcomes in hospitalised older patients: a retrospective cross-sectional study. The Pharmacogenomics Journal. 26(3)
Link to publisher’s version
Link to published version
Link to Version of Record
Type
Article